La vendita allo scoperto per BuzzFeed dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di BuzzFeed. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

BuzzFeed (NASDAQ:BZFD) Azioni, Report sulle vendite allo scoperto

BuzzFeed

BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.

BuzzFeed Inc

BrainStorm Cell Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent &amp; Trademark Office (USPTO) for patent application 16/981,757 which covers its proprietary exosome technology.&nbsp;

News

BCLI

BrainStorm Receives Notice Of Allowance fFr U.S. Patent On Innovative Exosome Platform Technology

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

Price Target

Reiteration

Analyst Ratings

CYTK

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

Biotech

Health Care

General

CRBP

The FDA Has Granted Fast Track Designation To Corbus Pharmaceuticals' CRB-701 For Relapsed Or Refractory Metastatic Cervical Cancer

JP Morgan analyst Brian Ossenbeck maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Overweight and raises the price target from $350 to $366.

JP Morgan Maintains Overweight on FedEx, Raises Price Target to $366

GILD

Gilead And Tubulis Enter Exclusive Option And License Agreement to Develop ADC Candidate For Select Solid Tumor Target; Tubulis To Receive $20M Upfront Payment And A Separate Option Exercise Fee Of $30M If Gilead Exercises Its Option, Tubilis Will Also Be Eligible For Up To $415M In Milestones Plus Royalties On Sales

<ul>
<li>Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels</li>
<li>Encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts</li>
<li>High levels of target coverage achieved with once daily dosing at all doses</li>
<li>Completion of dose escalation and initiation of dose expansion expected in 1H25</li>
<li>Additional efficacy data expected in 4Q25, including longer term major molecular response (MMR) rates</li>
</ul>

TERN

Terns Pharmaceuticals Announced Early Data From The Ongoing Dose Escalation Part Of The Phase 1 CARDINAL Study Evaluating TERN-701 In Patients With Relapsed/Refractory Chronic Myeloid Leukemia

Enbridge Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENB#TSX">ENB</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) (Enbridge or the Company) announced today that its Board of Directors has declared a quarterly dividend of C$0.9425 per common share, payable on March 1, 2025 to shareholders of record on February 14, 2025.&nbsp; The declared dividend represents a 3% increase from the prior quarterly rate and the thirtieth consecutive year in which the Company has increased its common share dividend.

Dividends

TSX:ENB

Enbridge Increases Quarterly Dividend By 3% To C$0.9425/Common Share, Payable March 1, 2025

<ul>
<li>This includes an upfront payment of $483.4 million, to be adjusted for inventory at close, and $75.0 million in potential net sales milestone payments. Coherus plans to use a portion of the transaction proceeds to fully repay the entirety of the Company's $230.0 million in existing convertible notes due April 2026 and $49.1 million to buy-out certain royalty obligations related to UDENYCA.</li>
<li>Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor.</li>
<li>Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine receptor 8 (CCR8) antibody.</li>
<li>Post-closing proceeds to repay the entirety of the company's $230 million convertible notes due April 2026</li>
</ul>

CHRS

Coherus Biosciences Has Agreed To Divest Udenyca (Pegfilgrastim) Franchise To Intas Pharmaceuticals For Up To $558.4M

U.S. stock futures were in negative territory during Tuesday&#8217;s premarket hours as the dollar slipped to 106.3 level.
The U.S. 10-year and two-year Treasury notes yielded 4.21% and 4.18%, respectively. Expectations of a further 25 basis point rate cut in December rose to 72.5%, according to <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">CME Group&#8217;s FedWatch tool</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.08%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.02%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.07%</td>
</tr>
<tr>
<td>Russel 2000</td>
<td>-0.11%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.01% to $603.60 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.09% to $514.84, according to <a href="https://www.benzinga.com/">Benzinga Pro</a> data.
Cues From The Last Session
The U.S. stock market closed higher on Monday, with the <a href="https://www.benzinga.com/24/12/42282669/sp-nasdaq-settle-at-record-highs-as-tesla-shares-surge-investor-sentiment-decreases-but-fear-greed-index-remains-in-greed-zone">S&amp;P 500 and Nasdaq Composite reaching new highs</a>.
Key Drivers:
<ul>
<li>Tesla Boost: Tesla shares surged 3.5% after Roth MKM upgraded the stock and raised its price target.</li>
<li>Super Micro Rebound: Super Micro Computer stock jumped 29% following a positive company announcement.</li>
<li>Economic Data: U.S. construction spending increased and the ISM manufacturing PMI rose, beating expectations.</li>
<li>Sector Performance: While most S&amp;P 500 sectors closed lower, communication services and consumer discretionary stocks outperformed. Utilities, real estate, and financials lagged.</li>
</ul>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.97%</td>
<td>19,404</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.24%</td>
<td>6,047.15</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.29%</td>
<td>44,782</td>
</tr>
<tr>
<td>Russel 2000</td>
<td>-0.02</td>
<td>2,434</td>
</tr>
</tbody>
</table>
</figure>
Also read: <a href="https://www.benzinga.com/markets/equities/24/12/42282948/ubs-forecasts-sp-500-to-hit-6600-in-2025-citing-support-from-over-easy-global-central-bank-policy">UBS Forecasts S&amp;P 500 To Hit 6,600 In 2025, Citing Support From &#8216;Over-Easy Global Central Bank Policy&#8217;</a>
Insights From Analysts: Chief investment officer at UBS Global Wealth Management, Mark Haefele termed the decade so far as the &#8220;Roaring 20s,&#8221; marked by high economic growth, strong market returns, and improving productivity.
In his ‘<a href="https://www.ubs.com/global/en/wealthmanagement/insights/chief-investment-office/roaring-20s-the-next-stage.html#review">UBS Year Ahead 2025 Report</a>‘ he said "After strong years for equities in 2023 and 2024, we see further upside in 2025. We expect the S&amp;P 500 to reach 6,600 by the end of 2025, around 10% higher than today&#8217;s levels."
"We expect central banks to cut interest rates further in the year ahead, reducing cash returns," Haefele added.
Highlighting his economic outlook he said, "In our base case, we expect sustained economic growth in the U.S., supported by healthy consumption, loose fiscal policy, and lower interest rates. Tariff threats are a headwind for Asia and Europe. If imposed, they could be partially offset by reactive stimulus measures in China."
Chief market strategist at Carson Group LLC, Ryan Detrick highlighted that &#8220;With a new high in December, we&#8217;ve seen new highs in 10 out of 12 months this year (April and August didn&#8217;t).&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Today was the 54th all-time high in &#39;24 for the S&amp;P 500. Officially the 5th most ever (since 1957 when it moved to 500 stocks). 62 in 2017 is next up. With a new high in December, we&#39;ve seen new highs in 10 out of 12 months this year (April and August didn&#39;t). Not bad. <a href="https://t.co/FiEJ27kjVr">pic.twitter.com/FiEJ27kjVr</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1863771861034668045?ref_src=twsrc%5Etfw">December 3, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Unrelated to past cycles, global central banks are easing monetary policy despite strong economic growth, high asset prices, and elevated inflation, said Bob Elliott, the chief investment officer at Unlimited Funds. Elliott presented the underlying data reiterating these conditions in a thread on X, indicating a positive sign for the markets.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The global economy is getting a shot of adrenaline from a coordinated central bank easing. But unlike the past, it comes at a time when growth is pretty good, asset prices are near highs, and inflation remains elevated. Thread.
&mdash; Bob Elliott (@BobEUnlimited) <a href="https://twitter.com/BobEUnlimited/status/1863551595545334237?ref_src=twsrc%5Etfw">December 2, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Upcoming Economic Data
This week&#8217;s economic calendar is packed after a short last week due to Thanksgiving.
<ul>
<li>On Tuesday, job openings data for October will be released at 10:00 a.m. ET and auto sales data will be released for which the time is yet to be determined.</li>
<li>On Wednesday, November&#8217;s data on ADP employment will be released at 8:15 a.m. ET.</li>
<li>St. Louis Fed President Musalem will speak at 8:45 a.m. ET.</li>
<li>The S&amp;P final U.S. services PMI for November will be released at 9:45 a.m. ET.</li>
<li>The ISM services and factory orders data for November and October, respectively, will be released at 10:00 a.m. ET.</li>
<li>Fed Beige Book will be released at 2:00 p.m. ET.</li>
<li>On Thursday, initial jobless claims data for November and U.S. trade deficit data for October will be released at 8:30 a.m. ET.</li>
<li>On Friday, the U.S. employment report, U.S. unemployment rate, and U.S. hourly wages data will be released at 8:30 a.m. ET.</li>
<li>The preliminary data for consumer sentiment will be released at 10 a.m. ET.</li>
<li>Chicago Fed President Goolsbee will speak at 10:30 a.m., ET.</li>
<li>Consumer credit data will be released at 3:00 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Shimmick Construction (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) was 57.5% higher at $4.43 apiece in premarket after it landed a $45.4 million contract to build the Murray Street Bridge in Santa Cruz.</li>
<li>Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)<a href="https://www.benzinga.com/24/12/42284776/super-micro-shares-rise-over-7-in-premarket-after-independent-special-committee-found-no-evidence-of-misconduct-but-top-investment-bank-flags-two-key-points-to-watch"> was 6.67% up</a> at $44.8 per share after it announced that the independent Special Committee formed by the company&#8217;s board completed its review.</li>
<li>Santi Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares were 4.50% down at $9.55 apiece after it secured a $37.6 million private placement financing through the sale of 16,713 shares of Series A Convertible Preferred Stock.</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares were down 1.3% to $352.44 apiece after Elon Musk&#8217;s pay package was rejected again by a Delaware judge despite being approved by Tesla shareholders at a June meeting.</li>
<li>Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) was up 0.17% at $23.97 per share after the retirement announcement of its chief executive officer, Pat Gelsinger.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session, advancing 0.91% to hover around $68.72.
The Dollar Index was down 0.12% to 106.3 level. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was down 0.16% over the past 24 hours and traded just over the $95K mark.
Major Asian markets closed higher on Tuesday. European markets were also upbeat. 
<ul>
<li>Read next: <a href="https://www.benzinga.com/24/12/42283257/charles-schwab-goldman-sachs-invesco-add-mara-holdings-morgan-stanley-cuts-stake-here-is-what-changed-with-mara-holdings-in-q3">Charles Schwab, Goldman Sachs Boosts MARA Stake As Stock Rallies 30% In Past 6 Months: Morgan Stanley, Other Major Funds Trim Positions In Q3</a></li>
</ul>
Image via Shutterstock

Equities

Markets

$BTC

INTC

SHIM

SMCI

SNTI

TSLA

US Stock Futures Dip As Dollar Slides And Treasuries Rise After S&P Hits 54th All-Time High This Year: Analyst Sees 'Further Upside' Of Around 10% In 2025 From Current Levels

Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced an exclusive global development and commercialization license agreement with Takeda (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) to advance elritercept. Elritercept is currently in two ongoing Phase 2 clinical trials; one in patients with very low-, low-, or intermediate-risk myelodysplastic syndrome ("MDS") and one in patients with myelofibrosis ("MF"). The Phase 3 RENEW clinical trial evaluating elritercept in adult patients with transfusion-dependent anemia with very low-, low-, or intermediate-risk MDS will begin enrollment soon.
Under the terms of the agreement, Takeda will obtain an exclusive license to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. Takeda will be responsible for all development, manufacturing and commercialization as of the effective date of the agreement. Subject to the terms of the agreement, Keros will receive a $200 million upfront cash payment and is eligible to receive development, approval and commercial milestones with the potential to exceed $1.1 billion. Keros will also be eligible to receive tiered royalties on net sales.

KROS

Takeda Tapped Keros Therapeutics Under A $200M Deal Along With Earn Out Of Over $1.1B To Boost Oncology Pipeline with Elritercept Beyond China, Hong Kong and Macau

ONCY

Oncolytics Biotech Completes Initial Safety Phase Enrollment For GOBLET Trial's Pancreatic Cancer Cohort

Jefferies analyst Brent Thill maintains DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Buy and raises the price target from $80 to $95.

DOCU

Jefferies Maintains Buy on DocuSign, Raises Price Target to $95

ROIV

Roivant Says Its Subsidiary Kinevant Sciences' Phase 2 RESOLVE-Lung Study Of Namilumab For Chronic Active Pulmonary Sarcoidosis Failed To Meet The Primary Endpoint, Further Development Of Namilumab For Sarcoidosis Will Be Discontinued

CRDO: 40% &#x7C; <a href="https://www.benzinga.com//node/42276828">Credo Technology shares are trading higher after the company reported better-than-expected Q2 financial results issued guidance that was above estimates.</a>
&nbsp;
CTNT: 247% &#x7C; <a href="https://www.benzinga.com//node/42282513">Cheetah Net Supply Chain Service Expands Operations With Acquisition Of TW &amp; EW Services</a>
&nbsp;
SHIM: 91% &#x7C; <a href="https://www.benzinga.com//node/42285910">Shimmick Construction Announced Monday It Has Been Awarded A $45.4M Contract To Complete Extensive Seismic Retrofitting And Improvements To The Murray Street Bridge At The Santa Cruz Small Craft Harbor</a>

Movers

Trading Ideas

CRDO

CTNT

Market-Moving News for December 3rd

Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care

AKBA

Akebia Therapeutics And U.S. Renal Care Enroll First Patient In Vafseo Outcomes VOICE Trial

The most oversold stocks in the financial sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Inter &amp; Co Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTR#NASDAQ">INTR</a>)</h3>
<ul>
<li>On Nov. 14, Inter &amp; Co posted better-than-expected quarterly sales. &#8220;We had a solid third quarter, reporting increased profitability and growth in both fee and interest income. Our focus on executing the 60/30/30 plan by increasing market share and product penetration, while we maintain efficiency gains is paying off.&#8221; The company's stock fell around 29% over the past month and has a <a href="https://www.benzinga.com/quote/INTR">52-week low of $4.32</a>.</li>
<li>RSI Value: 19.97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>INTR Price Action: Shares of Inter fell 1.3% to close at $4.56 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"> latest INTR new</a>s. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="932" height="816" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03035228/image-12.png" alt="" class="wp-image-674038" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03035228/image-12.png 932w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03035228/image-12-300x263.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03035228/image-12-768x672.png 768w" sizes="(max-width: 932px) 100vw, 932px" /></a></figure>
<h3 class="wp-block-heading">Nu Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Dec. 2, Citigroup downgraded its rating from Neutral to Sell on the stock and lowered its price target from $14.6 to $11. The company's stock fell around 14% over the past five days and <a href="https://www.benzinga.com/quote/NU">has a 52-week low</a> of $8.06.</li>
<li>RSI Value: 26.71</li>
<li>NU Price Action: Shares of Nu Holdings fell 4.2% to close at $12.00 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"> trend in NU stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03035304/image-13.png" alt="" class="wp-image-674044" style="width:577px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03035304/image-13.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03035304/image-13-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03035304/image-13-768x702.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">AppTech Payments Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APCX#NASDAQ">APCX</a>)</h3>
<ul>
<li>On Nov. 15, AppTech Payments reported a quarterly loss of 8 cents per share, which missed the analyst consensus estimate of a loss of 6 cents per share. &#8220;Our Q3 results reflect our focused approach to refining digital payment solutions and advancing strategic platform development to serve key sectors better,&#8221; said Luke D&#8217;Angelo, Chairman and CEO of AppTech. The company's stock fell around 37% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/APCX">low of $0.38</a>.</li>
<li>RSI Value: 25.34</li>
<li>APCX Price Action: Shares of AppTech Payments fell 12.5% to close at $0.42 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1">breakout in APCX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="888" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03035414/image-14.png" alt="" class="wp-image-674046" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03035414/image-14.png 888w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03035414/image-14-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03035414/image-14-768x720.png 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42267284/this-analyst-with-85-accuracy-rate-sees-more-than-8-upside-in-crowdstrike-here-are-5-stock-picks-for-november-from-wall-streets-most-accurate-analysts">This Analyst With 85% Accuracy Rate Sees More Than 8% Upside In CrowdStrike &#8211; Here Are 5 Stock Picks For November From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Long Ideas

Pre-Market Outlook

APCX

INTR

Top 3 Financial Stocks That Could Lead To Your Biggest Gains In Q4

Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it is in discussions and has an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding the evolving treatment landscape in endometrial cancer and any implications this may have with respect to the Company's Phase 3 XPORT-EC-042 trial. In light of this, Karyopharm does not plan to discuss its endometrial cancer program during the Piper Sandler 36th&nbsp;Annual Healthcare Conference being held in New York, NY today. The Company intends to provide an update on its endometrial cancer program as soon as practical following the discussion with FDA.

Government

Regulations

KPTI

Karyopharm Therapeutics Will Update On Endometrial Cancer Program Following US FDA Meet

Canaccord Genuity analyst Kingsley Crane maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Buy and raises the price target from $220 to $230.

Canaccord Genuity Maintains Buy on Zscaler, Raises Price Target to $230

ETON

Eton Pharmaceuticals Names Ipek Erdogan-Trinkaus As Chief Commercial Officer

Long-Term Outlook AT&amp;T expects to achieve the following 2025 and long-term financial targets through 2027. Beginning in the first quarter of 2025, and as a result of the pending disposition of our DIRECTV equity method investment, the Company plans to report adjusted EPS and free cash flow excluding earnings and cash flows related to DIRECTV. The Company continues to expect the sale of its entire 70% stake in DIRECTV to TPG to close in mid-2025. For comparability to these targets, the Company has provided a recast of historical results for these two financial measures in its Form 8-K dated December 3, 2024.
<ul>
<li>Consolidated service revenue growth in the low-single-digit range annually from 2025-2027.
<ul>
<li>Mobility service revenue growth in the 2% to 3% range annually.</li>
<li>Consumer fiber broadband revenue growth in the mid-teens annually.</li>
</ul>
</li>
<li>Adjusted EBITDA&#x2A; growth of 3% or better annually from 2025-2027.
<ul>
<li>Mobility EBITDA&#x2A; growth in the 3% to 4% range annually.</li>
<li>Consumer Wireline EBITDA&#x2A; grows at a double-digit compounded annual growth rate (CAGR) through 2027.</li>
<li>Business Wireline EBITDA&#x2A; declines at a low-double-digit CAGR through 2027; Business Solutions EBITDA&#x2A; approaching stabilization by the end of 2027.</li>
</ul>
</li>
<li>Capital investment&#x2A; in the $22 billion range annually from 2025-2027.</li>
<li>Free cash flow&#x2A;, excluding DIRECTV, of $16 billion+ in 2025, with annual growth of approximately $1 billion, resulting in free cash flow&#x2A; of $18 billion+ in 2027.
<ul>
<li>In addition, AT&amp;T expects to receive $5.4 billion of after-tax cash payments in 2025 and $0.5 billion in 2029 related to the sale of the DIRECTV investment.</li>
</ul>
</li>
<li>Adjusted EPS&#x2A;, excluding DIRECTV, of $1.97 to $2.07 in 2025, accelerating to double-digit percentage growth in 2027.</li>
<li>$3 billion+ in run-rate cost savings by the end of 2027, inclusive of the Company's target of achieving $2 billion+ in run-rate cost savings by mid-2026.</li>
</ul>

Guidance

AT&T Expects To Achieve $3B Cost Savings, $18B+ Free Cash Flow By 2027, And $40B+ Capital Returns

Stock Splits Continue Their 2024 Comeback

Netflix and BuzzFeed reportedly in talks to livestream 'Hot Ones' show

In a report released today, Jason Kreyer from Craig-Hallum assigned a Buy rating to BuzzFeed (BZFD – Research Report). The company's shares closed ...

BuzzFeed (BZFD) Gets a Buy from Craig-Hallum

Pre-earnings options volume in Buzzfeed (BZFD) is 1.8x normal with calls leading puts 19:1. Implied volatility suggests the market is anticipating ...

Buzzfeed options imply 21.1% move in share price post-earnings

Reports Q3 revenue $64.32M vs. $59.98M last year. Q3 revenues exceeded the company's outlook, growing 7% year-over-year, with strong growth in two ...

BuzzFeed reports Q3 EPS 5c  vs. (33c) last year

Buzzfeed GAAP EPS of $0.05, revenue of $64.32M

Buzzfeed Inc ( ($BZFD) ) has released its Q3 earnings. Here is a breakdown of the information Buzzfeed Inc presented to its investors. BuzzFeed Inc...

BuzzFeed Inc. Reports Strong Q3 Financial Performance

BuzzFeed, Inc. (BZFD) Q3 2024 Earnings Call Transcript

The Art Of Being A Contrarian With Courage & Conviction Investing

BuzzFeed: This Rally Can Last Longer

AMZN

AVGO

BIRD

BZFD

BZFDW

CNVS

CURI

CURIW

CVNA

GOOG

GOOGL

JBLU

MESA

NFLX

NVDA

NYCB

QGEN

RENT

RRGB

SAVEQ

SITC

ZETA

Press Releases

BuzzFeed, Inc. Makes Strategic & Organizational Changes to Improve Profitability After Challenging Q4 and Full Year 2023

The Independent and BuzzFeed Sign Long-Term License and Strategic Partnership in UK & Ireland

BuzzFeed, Inc. to Release First Quarter 2024 Financial Results on Monday, May 13, 2024

BuzzFeed, Inc. Announces 1-For-4 Reverse Stock Split

BuzzFeed, Inc. First Quarter 2024 Financial Results in Line With March Outlook

BuzzFeed Inc., Bullish About Future of the Company, Redefines Compensation Model to Drive Value Creation

BuzzFeed, Inc. to Release Second Quarter 2024 Financial Results on Monday, August 12, 2024

BuzzFeed, Inc. Posts Strong Q2 Financial Results and Expects Continued Improvement in Q3

BuzzFeed, Inc. to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

BuzzFeed, Inc. Delivers Strong Q3 Financial Results

Angi

The Arena Group Holdings, Inc. Common Stock

Arena Group Holdings

Bumble

Cheer Holding, Inc. - Class A Ordinary Share

Cheer Holding

DHI Group

EverQuote

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Phoenix New Media

FuboTV

Giftify

IZEA Worldwide

Nextdoor Holdings, Inc. Class A Common Stock

Nextdoor Holdings

36Kr Holdings Inc. - American Depositary Shares

36KR Holdings

MediaAlpha

MoneyHero Limited - Class A Ordinary Shares

MoneyHero

Outbrain

PSQ Holdings

System1

So-Young International Inc. - American Depository Shares

So-Young Intl

TrueCar

trivago N.V. - American Depositary Shares

trivago

Travelzoo

Yalla Group Limited American Depositary Shares, each representing one Class A Ordinary Share

Yalla Group

Zedge

Zhihu Inc. American Depositary Shares, each representing three (3) Class A Ordinary Shares

Comments

BuzzFeed

Vendite allo scoperto

BuzzFeed (NASDAQ:BZFD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO